Testosterone Screening in Military: Lab Protocols & Clinical Thresholds

The DoD Testosterone Screening Initiative: What Clinicians Need to Know

The announcement of a Department of Defense protocol to screen active-duty personnel for low testosterone and offer hormone replacement therapy represents a significant shift in military occupational health policy. This development warrants careful clinical examination—specifically, how screening thresholds are defined, which assays drive candidacy decisions, and what baseline metabolic profiling should precede any HRT initiation.

Why Testosterone Screening in a Military Context?

Hypogonadism prevalence in the U.S. has risen over the past two decades. Studies suggest 15–20% of men over 40 have total testosterone <300 ng/dL. Military populations face unique stressors—chronic cortisol elevation, sleep disruption, high-intensity physical demand—all of which suppress the hypothalamic-pituitary-gonadal (HPG) axis. When cortisol remains elevated, CRH and ACTH suppress GnRH release, reducing LH and FSH output, which directly downregulates testicular testosterone synthesis.

Physically demanding occupations also deplete micronutrients—particularly zinc and magnesium—that are essential cofactors for 17β-HSD (the enzyme that converts androstenedione to testosterone) and for maintaining GnRH pulse frequency.

The Laboratory Framework: What Should Be Ordered?

Before any testosterone replacement decision, a complete baseline panel is non-negotiable:

Primary Hormones:

• Total testosterone (LC-MS/MS preferred; immunoassay is inferior)
• Free testosterone (equilibrium dialysis or direct LC-MS/MS, not calculated)
• SHBG (sex hormone-binding globulin)
• LH and FSH (assess whether hypogonadism is primary or secondary)

Metabolic Context:

• Thyroid panel: TSH, free T3, free T4 (TSH >2.5 mIU/L may indicate subclinical hypothyroidism, which impairs testosterone synthesis)
• Cortisol (8 AM fasting, or 24-hour urine free cortisol if Cushing's suspected)
• DHEA-S (androgen reserve; <150 μg/dL suggests adrenal insufficiency)
• Prolactin (suppresses GnRH; >25 ng/mL warrants pituitary imaging)

Hepatic & Lipid Integrity:

• AST, ALT, GGT, albumin, bilirubin
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• HbA1c and fasting glucose

Micronutrient Status:

• Serum zinc, magnesium RBC, vitamin D25-OH (aim for 40–60 ng/mL)
• Homocysteine, methylmalonic acid (B12 and folate adequacy)

Interpreting the Testosterone Result: Optimal vs. Reference Range

This is where clinical nuance matters. Reference ranges (typically 264–916 ng/dL for total testosterone) are population-derived statistics—not optimization targets.

Optimal ranges for symptomatic improvement and metabolic health:

• Total testosterone: 600–900 ng/dL (upper-normal, not supraphysiologic)
• Free testosterone: 15–25 pg/mL
• SHBG: 24–122 nmol/L (higher SHBG may reduce bioavailable testosterone despite normal total levels)

A man with total testosterone of 380 ng/dL may fall within the reference range but below the threshold for symptom resolution. Equally important: if LH and FSH are suppressed (<2 IU/L), the hypogonadism is secondary (central), suggesting pituitary or hypothalamic dysfunction—HRT must address the root cause, not merely replace testosterone.

HRT Candidacy: Beyond a Single Number

The DoD policy should emphasize that testosterone replacement candidacy requires:

1. Persistent symptoms (fatigue, reduced libido, decreased muscle mass despite adequate training) and lab evidence of low testosterone on repeated testing (at least 2 measurements)
2. Exclusion of secondary causes: thyroid dysfunction, prolactin elevation, cortisol dysregulation, vitamin D/zinc deficiency
3. Baseline metabolic health: normal fasting glucose, HbA1c <5.7%, lipids within optimal ranges
4. Absence of contraindications: active prostate cancer, severe sleep apnea (untreated), uncontrolled polycythemia

Synergistic Supplementation During HRT Monitoring

If a service member is initiated on testosterone therapy, concurrent supplementation optimizes outcomes and mitigates side effects:

• Magnesium glycinate: 400–500 mg daily (supports sleep quality, GABA signaling, cortisol buffering)
• Zinc picolinate: 25–50 mg daily (essential for 17β-HSD and LH/FSH signaling)
• Vitamin D3 + K2 (MK-7): 4,000–5,000 IU D3 + 90 μg K2 daily (synergizes with testosterone for bone mineralization and cardiovascular health)
• NAC (N-acetylcysteine): 1,200–1,800 mg daily (glutathione precursor; supports detoxification during hormone metabolism)
• Omega-3 (EPA/DHA): 2–3 g combined daily (reduces inflammation, supports lipid management—important as testosterone can raise triglycerides)

Monitoring Protocol During HRT

Once HRT is initiated, the DoD should implement quarterly labs for the first year:

• Total testosterone, free testosterone, SHBG
• Hematocrit (testosterone increases RBC production; hematocrit >52% requires phlebotomy)
• Lipid panel and liver function tests
• PSA (baseline and annually; <4.0 ng/mL is reassuring; rapid increase warrants urology referral)
• Blood pressure (testosterone can elevate BP; monitor at each visit)

After 12 months of stable dosing, semiannual monitoring suffices if metrics remain stable.

Bottom Line

The DoD testosterone screening initiative is evidence-informed—low testosterone does impair military performance and occupational health. However, successful implementation hinges on rigorous lab protocols, clear candidacy criteria beyond a single testosterone number, and concurrent investigation of secondary causes. Providers must distinguish between reference ranges and optimal ranges, exclude confounders (thyroid, cortisol, micronutrient deficiency), and implement robust monitoring. When executed with this level of precision, testosterone replacement therapy can restore performance, strength, and metabolic health in affected service members.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.